bg content top team

Meet our Experienced
and Multidisciplined Team

Board of Directors

Mark A. Sirgo, Pharm. D, Chairman
Mark was most recently President and CEO of BioDelivery Sciences (BDSI: Nasdaq) during which time he oversaw three drug approvals and created a fully integrated pharmaceutical company in the field of pain and addiction medicine. Prior to this, he spent 16 years in a variety of positions of increasing responsibility in both clinical development and marketing at Glaxo, Glaxo Wellcome, and GlaxoSmithKline, including Vice President of International OTC Development and Vice President of New Product Marketing. Dr. Sirgo was responsible for managing the development and FDA approval of Zantac 75 while at Glaxo Wellcome. From 1996 to 1999, Mark was Senior Vice President of Global Sales and Marketing at Pharmaceutical Product Development (PPDI: Nasdaq). Dr. Sirgo received his BS in Pharmacy from the Ohio State University and his Doctorate from Philadelphia College of Pharmacy and Science.

Nissim Darvish, M.D., Ph.D., Director
Nissim is a Senior Managing Director at OrbiMed Healthcare Fun Management, a veteran of the life science industry, and has 15 years of experience in covering medical technology development, corporate leadership and investment management. He spent 8 years with Pitango Venture Capital, where he was a General Partner managing life sciences investments. Previously, Nissim was the founder and CEO of Impulse Dynamics, which he led for 6 years, culminating in a $250 million realization event. Nissim obtained his M.D. and Ph.D. in Biophysics and Physiology from the Technion in Israel, and subsequently conducted his post-doctoral research at NIH. He has published over 100 patents and authored over 20 publications.

Michael Rice, Director
Michael Rice is a Founding Partner of LifeSci Advisors and LifeSci Capital. Michael was the co-head of health care investment banking at Canaccord Adams, where he was involved in debt and equity financing. Michael is a former Managing Director at Think Equity Partners where he was responsible for managing Healthcare Capital Markets – including the structuring and execution of numerous transactions. Michael also served as a Managing Director at Banc of America specializing in large hedge funds and private equity healthcare funds. Previously, he was a Managing Director at JPMorgan/Hambrecht & Quist.

June S. Almenoff, M.D., Ph.D., Director
June S. Almenoff is currently COO and Chief Medical Officer at Innovate Biopharmaceuticals. Dr. Almenoff was previously President and Chief Medical Officer of Furiex Pharmaceuticals (FURX: Nasdaq) until FURX was acquired by Actavis in 2014. Formerly the Vice President in the Clinical Safety organization at GSK, June chaired a Pharma-FDA working group, and also worked in the area of scientific licensing. Prior to joining GSK, Dr. Almenoff served on the faculty of Duke University School of Medicine, where she is currently an adjunct Professor.

Ariel Moses, Director
Ariel is a Managing Partner and CFO at Agate Medical Investments. Agate has managed VC funds since 2007 and has focused on MedTech spanning 25 companies in Israel, Asia, the US, and Europe. Prior to joining Agate, Ariel founded and lead a FinTech company within one of Israel's leading investment corporations. Ariel has extensive experience in corporate finance and fund management and is a Board member in 6 MedTech companies. Formerly an active board member in 'Iscare' – a European healthcare company active in IVF, plastic surgery, IBD treatments, and general surgery – he successfully exited in 2017. Ariel holds a B.A. in Economics and an L.L.B. from the Hebrew University in Jerusalem.

Isaac Israel, Director
Mr. Israel currently serves as CEO of Kitov Pharmaceuticals (TASE:KTOV). Isaac is also the Vice President of Business Development at Capital Point Ltd., a company focused on funding high-tech ventures, primarily in medical devices, biotechnology & environmental technologies. Mr. Israel founded and managed BeeContact Communications, a public company in the field of cellular communications and Uneri Capital, a company that provides financial and business consulting services to start-up companies.

Arie Giniger, Ph.D., Director
Dr. Giniger’s business career in the pharmaceutical and cosmetics fields spans more than 40 years. Beginning as a scientist with Schering Plough (USA), Dr. Giniger joined Taya Israel Cosmetic Company, first as a chemist and ultimately as Managing Director. He then joined Agis Group (Israel) as the Managing Director of their Careline Cosmetics division and then as Commercial Manager of the entire Agis Group. He is the founder of Private Cord Blood Bank, Sheba Medical Center, Israel’s largest umbilical cord blood bank. He received a B.Sc. in Chemistry from Israel’s Technion in Haifa and holds a Ph.D. in Pharmaceutical Sciences from Columbia University in New York.

 

Team-icon

Our team is balanced by responsible stewardship and innovative drive.

 

CURRENT INVESTORS:
    •    OrbiMed Advisors
    •    Ofakim Hi-Tech Ventures
    •    Capital Point Ltd.
    •    Pharmascience
    •    Agate Medical
         Investments

Info-iconRDD is a specialty pharma company developing targeted pharmacological treatments for diseases of the anorectal region such as anal fissures, fecal incontinence and pruritus ani. A pharmaceutical compound targeting radiation proctitis is in preclinical development as well.

The company utilizes a high-reward, low-risk business model by repurposing drugs. By choosing medications that are already approved for other indications and combining them with our proprietary drug-delivery technology, we benefit from a short regulatory route while maintaining patent protection.

Copyright © 2018, RDD Pharma, Ltd. All rights reserved.

 

Menu
Go to top